Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Current Hematologic Malignancy Reports

Volumn 11, Issue 6, 2016, Pages 462-467

  Pemmaraju, Naveen ^a   Gupta, Vikas ^b   Thompson, Michael A ^c   Lane, Andrew A ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c Aurora Health Care   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BPDCN; BPDCN; Disease specific hashtag; Rare disease; Social media; Twitter

Indexed keywords

CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN;

CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); HEALTH CARE ORGANIZATION; HUMAN; INTERNET; MALIGNANT NEOPLASTIC DISEASE; MEDICOLEGAL ASPECT; OVERALL SURVIVAL; PLASMACYTOID DENDRITIC CELL; REVIEW; SOCIAL MEDIA; CYTOLOGY; DENDRITIC CELL; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; MEDICAL INFORMATION SYSTEM; METABOLISM; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; PSYCHOLOGY;

DENDRITIC CELLS; HEALTH INFORMATION EXCHANGE; HEMATOLOGIC NEOPLASMS; HUMANS; INTERNET; MYELOPROLIFERATIVE DISORDERS; SOCIAL MEDIA;

EID: 84983009720     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-016-0340-3     Document Type: Review

References (35)

1. Andrew P, Vickers MM, O'Connor S, Valdes M, Tang PA. Media reporting of practice-changing clinical trials in oncology: a North American perspective. Oncologist. 2016;21(3):269–78.
2. Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social media and the practicing hematologist: twitter 101 for the busy healthcare provider. Curr Hematol Malig Rep. 2015;10(4):405–12.
3. Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26(9):782, 784–5, 791.
4. Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (mpn)-focus on twitter and the development of a disease-specific community: #mpnsm. Curr Hematol Malig Rep. 2015.
5. Thompson MA. Using social media to learn and communicate: it is not about the tweet. Am Soc Clin Oncol Educ Book. 2015;206–211. doi:10.14694/EdBook_AM.2015.35.206.
6. Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33:6520.
7. Attai DJ, Sedrak MS, Katz MS, et al. Social media in cancer care: highlights, challenges & opportunities. Future Oncol. 2016.
8. Xu S, Markson C, Costello KL, Xing CY, Demissie K, Llanos AA. Leveraging social media to promote public health knowledge: example of cancer awareness via twitter. JMIR Public Health Surveillance. 2016;2(1):e17.
9. Attai DJ, Cowher MS, Al-Hamadani M, Schoger JM, Staley AC, Landercasper J. Twitter social media is an effective tool for breast cancer patient education and support: patient-reported outcomes by survey. J Med Internet Res. 2015;17(7):e188.
10. Savage N. Scientists in the twitterverse. Cell. 2015;162(2):233–4.
11. Thompson MA. Social media in clinical trials. Am Soc Clin Oncol Educ Book. 2014;e101-105. doi:10.14694/EdBook_AM.2014.34.e101.
12. Perales MA, Drake EK, Pemmaraju N, Wood WA. Social media and the adolescent and young adult (AYA) patient with cancer. Curr Hematol Malig Rep. 2016.
13. Borgmann H, Woelm JH, Merseburger A, et al. Qualitative twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference. Can Urol Assoc J. 2016;10(1–2):39–44.
14. Borgmann H, Loeb S, Salem J, et al. Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. Urol Oncol. 2016.
15. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.
16. Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055–61.
17. Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–46.
18. Pemmaraju N ea. Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): male predominance, propensity for extra-medullary involvement, and poor outcomes. ASCO Annual Meeting. 2014.
19. Laribi K, Denizon N, Besancon A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357–67.
20. Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9):10174–81.
21. Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and hypercvad therapy. Am J Hematol. 2016;91(3):283–6.
22. Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14(4):220–2.
23. Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125(23):3559–62.
24. Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1006–12.
25. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomarker research. 2014;2(1):4.
26. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–84.
27. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–92.
28. LA Pemmaraju N, Sweet KL, Stein A, Sumithira V, Blum WG. Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing. J Clin Oncol. 2016;34:7006.
29. Wells DM, Lehavot K, Isaac ML. Sounding off on social media: the ethics of patient storytelling in the modern era. Acad Med. 2015;90(8):1015–9.
30. Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637–46.
31. Dimov V, Eidelman F. Utilizing social networks, blogging and youtube in allergy and immunology practices. Expert Rev Clin Immunol. 2015;11(10):1065–8.
32. Grajales 3rd FJ, Sheps S, Ho K, Novak-Lauscher H, Eysenbach G. Social media: a review and tutorial of applications in medicine and health care. J Med Internet Res. 2014;16(2):e13.
33. Lewis MA, Dicker AP. Social media and oncology: the past, present, and future of electronic communication between physician and patient. Semin Oncol. 2015;42(5):764–71.
34. Launer J. The age of twitter. Postgrad Med J. 2013;89(1057):675–6.
35. Sedrak MS, Cohen RB, Merchant RM, Schapira MM. Cancer communication in the social media age. JAMA Oncol. 2016;2(6):822–3.